CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2542 Tracheotomy Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D011665 Pulmonary Valve Insufficiency NIH 0.41
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0010444 Pulmonary insufficiency HPO 0.41

There is one clinical trial.

Clinical Trials


1 Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

NCT04452669 COVID-19 Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)

Primary Outcomes

Description: Number of participants that require ECMO Number of participants that cannot be extubated within 10 days or A downward change in Oxygenation Index by >15% from baseline

Measure: Reduction in Respiratory Failure

Time: 10 days

Description: Number of participants that require ECMO Number of participants requiring inotropic therapy Number of participants that require mechanical circulatory support A change in Cardiac Troponin >20% from baseline or A change in BNP >15% from baseline

Measure: Reduction in Cardiac/Circulatory Failure

Time: 10 days

Secondary Outcomes

Description: Number of participants that demonstrate a change in FiO2 by 50% or more.

Measure: Improvement in Oxygenation

Time: 10 days

Description: Number of participants with a reduction in the time to extubation Number of participants with a reduction in ICU days Number of participants with a reduction in hospital days

Measure: Improved Clinical Outcomes

Time: 28 days


No related HPO nodes (Using clinical trials)